Investor Information
News
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L EGFRm NSCLC
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L EGFRm NSCLC